Asymmetric Dimethylarginine Plasma Concentrations Differ in Patients with End-Stage Renal Disease: Relationship to Treatment Method and Atherosclerotic Disease
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide (NO) synthase. Its concentration is elevated in patients with end-stage renal disease (ESRD), in part because it is excreted via the kidneys. In this study, the plasma concentrations of ADMA, symmetric dimethylarginine, and L-arginine were determined in relation to plasma nitrate levels (as an index of NO formation) for a group of 80 patients with ESRD. The effects of two treatment methods, i.e., hemodialysis (HD) and peritoneal dialysis (PD), and the role of the presence of atherosclerotic disease were evaluated. Forty-three patients receiving HD and 37 patients receiving PD were compared with healthy control subjects. Plasma L-arginine and dimethylarginine levels were determined by HPLC, using precolumn derivatization with o-phthaldialdehyde. Plasma nitrate levels were determined by gas chromatography-mass spectrometry. Predialysis ADMA concentrations in HD-treated patients were approximately sixfold higher than those in the control group (6.0 ± 0.5 versus 1.0 ± 0.1 μmol/L; P < 0.05). Plasma nitrate concentrations were significantly lower in HD-treated patients, which suggests that ADMA may inhibit NO synthase. In contrast, plasma ADMA levels and nitrate concentrations in PD-treated patients were similar to those in control subjects. Plasma L-arginine concentrations were not significantly decreased in patients with ESRD. ADMA concentrations were significantly decreased 5 h after HD, compared with baseline values. ADMA levels were significantly higher in HD-treated patients with manifest atherosclerotic disease than in HD-treated patients without atherosclerotic disease (7.31 ± 0.70 versus 3.95 ± 0.52 μmol/L; P < 0.05). This study confirms that ADMA is accumulated in ESRD. PD-treated patients exhibit significantly lower ADMA levels than do HD-treated patients. Accumulation of ADMA may be a risk factor for the development of endothelial dysfunction and cardiovascular disease in patients with ESRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
Accelerated Atherosclerosis in Prolonged Maintenance Hemodialysis
Lindner, A., Charra, B., Sherrard, D. J., & Scribner, B. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197403282901301 · Cited by 1,776
Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.
Förstermann, U., Closs, E. I., Pollock, J. S., Nakane, M., Schwarz, P., Gath, I., & Kleinert, H. (1994) · Hypertension · doi:10.1161/01.hyp.23.6.1121 · Cited by 1,111
Rees, D. D., Palmer, R. M. J., Hodson, H. F., & Moncada, S. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb11833.x · Cited by 850
Baylis, C., Mitruka, B., & Deng, A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115849 · Cited by 729
Cayatte, A. J., Palacino, J. J., Horten, K., & Cohen, R. A. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.5.753 · Cited by 493
Böger, R. H., Bode-Böger, S. M., Thiele, W., Junker, W., Alexander, K., & Frölich, J. C. (1997) · Circulation · doi:10.1161/01.cir.95.8.2068 · Cited by 490
Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis
Vallance, P., Leone, A., Calver, A., Collier, J., & Moncada, S. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199204002-00018 · Cited by 469
Cited by
Zoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07217-8 · Cited by 1,087
Self-citationOxidative stress in end-stage renal disease: an emerging threat to patient outcome
Locatelli, F., Canaud, B., Eckardt, K.-U., Stenvinkel, P., Wanner, C., & Zoccali, C. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg074 · Cited by 758
Homocysteine Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine
Stühlinger, M. C., Tsao, P. S., Her, J.-H., Kimoto, M., Balint, R. F., & Cooke, J. P. (2001) · Circulation · doi:10.1161/hc4601.098514 · Cited by 662
Lin, K. Y., Ito, A., Asagami, T., Tsao, P. S., Adimoolam, S., Kimoto, M., Tsuji, H., Reaven, G. M., & Cooke, J. P. (2002) · Circulation · doi:10.1161/01.cir.0000027109.14149.67 · Cited by 651
Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor
Stühlinger, M. C. (2002) · JAMA · doi:10.1001/jama.287.11.1420 · Cited by 581
Does ADMA Cause Endothelial Dysfunction?
Cooke, J. P. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.9.2032 · Cited by 581
Schwedhelm, E., Maas, R., Freese, R., Jung, D., Lukacs, Z., Jambrecina, A., Spickler, W., Schulze, F., & Böger, R. H. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02990.x · Cited by 494
Self-citationBöger, R. H., Sydow, K., Borlak, J., Thum, T., Lenzen, H., Schubert, B., Tsikas, D., & Bode-Böger, S. M. (2000) · Circulation Research · doi:10.1161/01.res.87.2.99 · Cited by 479
Sydow, K., & Münzel, T. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00033-3 · Cited by 433
Teerlink, T., Nijveldt, R. J., de Jong, S., & van Leeuwen, P. A. M. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5575 · Cited by 417
Nitric oxide deficiency in chronic kidney disease
Baylis, C. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00424.2007 · Cited by 413
Kielstein, J. T., Impraim, B., Simmel, S., Bode-Böger, S. M., Tsikas, D., Frölich, J. C., Hoeper, M. M., Haller, H., & Fliser, D. (2004) · Circulation · doi:10.1161/01.cir.0000105764.22626.b1 · Cited by 401
Self-citationThe emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
BOGER, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00500-5 · Cited by 393
Kielstein, J. T., Bo[Combining Diaeresis]ger, R. H., Bode-Bo[Combining Diaeresis]ger, S. M., Fro[Combining Diaeresis]lich, J. D. C., Haller, H., Ritz, E., & Fliser, D. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v131170 · Cited by 369
Self-citationBöger, R. H. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.10.2842s · Cited by 363
Self-citationThe l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio
BODEBOGER, S., SCALERA, F., & IGNARRO, L. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.002 · Cited by 347
The Clinical Pharmacology of L-Arginine
Böger, R. H., & Bode-Böger, S. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.79 · Cited by 331
Self-citationThe Determinants of Endothelial Dysfunction in CKD: Oxidative Stress and Asymmetric Dimethylarginine
Yilmaz, M. I., Saglam, M., Caglar, K., Cakir, E., Sonmez, A., Ozgurtas, T., Aydin, A., Eyileten, T., Ozcan, O., Acikel, C., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.09.029 · Cited by 331
Zoccali, C., Benedetto, F. A., Maas, R., Mallamaci, F., Tripepi, G., Salvatore Malatino, L., & Bo[Combining Diaeresis]ger, R. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v132490 · Cited by 319
Fliser, D., Kronenberg, F., Kielstein, J. T., Morath, C., Bode-Bo[Combining Diaeresis]ger, S. M., Haller, H., & Ritz, E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005020179 · Cited by 312
Self-citationThe Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels
Toda, N., & Okamura, T. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.3 · Cited by 308
Endothelial Dysfunction Induced by Hyperhomocyst(e)inemia: Role of Asymmetric Dimethylarginine
Stühlinger, M. C., Oka, R. K., Graf, E. E., Schmölzer, I., Upson, B. M., Kapoor, O., Szuba, A., Malinow, M. R., Wascher, T. C., Pachinger, O., et al. (2003) · Circulation · doi:10.1161/01.cir.0000085067.55901.89 · Cited by 303
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease
Silverstein, D. M. (2009) · Pediatric Nephrology · doi:10.1007/s00467-008-1046-0 · Cited by 300
Oxidative Stress in Hemodialysis Patients: A Review of the Literature
Liakopoulos, V., Roumeliotis, S., Gorny, X., Dounousi, E., & Mertens, P. R. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3081856 · Cited by 297
NIJVELDT, R. (2003) · Clinical Nutrition · doi:10.1054/clnu.2002.0613 · Cited by 256
Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management
Van Buren, P. N., & Toto, R. (2011) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.10.003 · Cited by 256
Total nitric oxide production is low in patients with chronic renal disease
Schmidt, R. J., & Baylis, C. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00281.x · Cited by 252
Endogenous nitric oxide synthase inhibitors are responsible for the L‐arginine paradox
Tsikas, D., Böger, R. H., Sandmann, J., Bode-Böger, S. M., & Frölich, J. C. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01686-0 · Cited by 237
Self-citationArginine, arginine analogs and nitric oxide production in chronic kidney disease
Baylis, C. (2006) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0143 · Cited by 237
Nitric oxide and penile erectile function
TODA, N., AYAJIKI, K., & OKAMURA, T. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.011 · Cited by 229
Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension
Kielstein, J. T., Bode-Böger, S. M., Hesse, G., Martens-Lobenhoffer, J., Takacs, A., Fliser, D., & Hoeper, M. M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000168414.06853.f0 · Cited by 220
Self-citationYoo, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00444-0 · Cited by 210
Vascular Incompetence in Dialysis Patients—Protein‐Bound Uremic Toxins and Endothelial Dysfunction
Jourde‐Chiche, N., Dou, L., Cerini, C., Dignat‐George, F., & Brunet, P. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.00925.x · Cited by 187
Nitric Oxide Dysfunction in the Pathophysiology of Preeclampsia
Lowe, D. T. (2000) · Nitric Oxide · doi:10.1006/niox.2000.0296 · Cited by 174
Asymmetric Dimethylarginine: A Cardiovascular Risk Factor and a Uremic Toxin Coming of Age?
Kielstein, J. T., & Zoccali, C. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.05.009 · Cited by 173
Self-citationThe liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA)
NIJVELDT, R. (2003) · Clinical Nutrition · doi:10.1054/clnu.2002.0612 · Cited by 166
Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo
Rooyakkers, T. M., Stroes, E. S. G., Kooistra, M. P., Van Faassen, E. E., Hider, R. C., Rabelink, T. J., & Marx, J. J. M. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1009.x · Cited by 157
Davis, J. S., & Anstey, N. M. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181ffd9f7 · Cited by 86
Böger, R. H., Maas, R., Schulze, F., & Schwedhelm, E. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.196 · Cited by 65
Self-citationMicrobiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD
Briskey, D., Tucker, P. S., Johnson, D. W., & Coombes, J. S. (2016) · Nitric Oxide · doi:10.1016/j.niox.2016.05.002 · Cited by 47
Cakir, E., Ozcan, O., Yaman, H., Akgul, E. O., Bilgi, C., Erbil, M. K., & Yesilova, Z. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2045 · Cited by 28
“conditions, including end-stage chronic renal failure (22),”
Metadata
- Authors
- KIELSTEIN, J. T., BÖGER, R. H., BODE-BÖGER, S. M., SCHÄFFER, J., BARBEY, M., KOCH, K. M., & FRÖLICH, J. C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1999-03
- Volume
- 10
- Issue
- 3
- Pages
- 594-600
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2151296579
- Cited by
- 361
- References
- 34
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.